AMR Action Fund

I was honored to participate in an AMR Symposium today hosted by the Global Coalition on Aging and Acton Institute at The Pontifical Academy of Sciences in Vatican City representing the AMR Action Fund

The “Breakthroughs on the Brink” section of this Global Health Technologies Coalition (GHTC) AMR overview highlights several promising antimicrobials in late-stage development. Without pull incentives in place, however, the companies innovating these therapies are likely to face significant market challenges and the therapies may not get to patients in need. Full analysis here: https://lnkd.in/eAnCZJXF

Just before the High-level Meeting on #AMR at the United Nations last month, AMR Action Fund teamed up with Foreign Policy, pulling together a diverse group of stakeholders to participate in a simulation that highlighted the complex policy, financial and public health challenges posed by outbreaks of drug-resistant bacteria. The event drew participants from government ministries, NGOs, and industry, and netted some key takeaways, including the need for improved diagnostics and surveillance data, coordinating efforts across sectors, and pull incentives to drive sustainable investment in clinical-stage R&D. My sincere hope is that the global community - especially G7 governments - will not let the momentum of the past year wane. Bacteria evolve, it is what the do. We need to evolve as well. Many thanks to CARB-X , Cepheid , Merck , Northwestern Buffett Institute for Global Affairs AMR Working Group, Pfizer and Viatris for also supporting the simulation. The FP Analytics Synthesis Report can be found here: https://lnkd.in/eUWbUfM5

A harrowing patient story from the UK of a man who has run out of treatment options for a nasty staph infection and is pursuing phage therapy. “I’ve had numerous pills, potions, antibiotics, transfusions and none of them worked. We have exhausted the available options and are down to phage which was raised as a last resort,” Mr Stocking said. "I am 81 and I can’t pioneer much more with my life so whatever I can do to be of use to anybody then let’s give it a go." #AMR via The Telegraph https://lnkd.in/eDqpZcWn

The threat of drug-resistant fungal infections is growing while investments into innovative anti-fungal diagnostics & therapies are lacking, writes Norman van Rhijn in The Conversation UK. More here: bit.ly/4hhWI78 #AMR

A new Nature study found that rifaximin, an antibiotic commonly used to treat liver disease, causes resistance to daptomycin, one of the few drugs that is effective against vancomycin-resistant enterococcus: https://lnkd.in/d_aRbyZH

Congratulations to TenNor Therapeutics. The company’s lead asset, rifaquizinone, has the potential to become the first new drug developed specifically for Helicobacter pylori infection in more than 30 years. Learn more: https://lnkd.in/exnU7XmV

Sepsis, closely tied to #AMR, is responsible for nearly 14 million deaths each year but remains under-prioritized globally. Tomorrow, Deepali Patel will participate in a discussion exploring policies that integrate efforts to address these twin threats, ensuring stronger health systems and better global health outcomes. Learn more: https://lnkd.in/dNSEwjyH #UNITEGlobalSummit

Four sessions on #AMR tomorrow at the World Health Summit, with the Fund’s Deepali Patel chairing a discussion on innovation and access. Livestream link 👇

It is encouraging to see the G7 once again express its support for “tackling market failures of novel antimicrobial R&D, including through innovative market sustainable approaches.” The group specifically noted that it is reinforcing its “commitment to continue to expedite the urgent implementation of effective pull incentives in our regional and domestic markets and health systems.” Urgency is key. Read the full communique here: https://lnkd.in/e2PXzysy